Nephrology Drugs Global Market Report 2024

Key drug types in nephrology include antihypertensive agents, erythropoiesis-stimulating agents, diuretics, ACE inhibitors, antidiabetic agents, and others. Antihypertensive drugs, for instance, are a diverse class used to manage high blood pressure, offering various mechanisms of action. These medications are administered through different routes such as oral, parenteral, and others, and are distributed through hospital pharmacies, online platforms, and retail pharmacies. Major users include hospitals, homecare settings, specialty clinics, and various other end-users.

The nephrology drug market research report provides nephrology drug market statistics, including nephrology drug industry global market size, regional shares, competitors with a nephrology drug market share, detailed nephrology drug market segments, market trends and opportunities, and any further data you may need to thrive in the nephrology drug industry. This nephrology drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nephrology drugs market has grown strongly in recent years. It will grow from $16.18 billion in 2023 to $17.08 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. Historical growth can be attributed to several factors, including the increasing prevalence of chronic kidney diseases (CKD), advancements in drug development, greater awareness and improved diagnosis, government initiatives and healthcare policies supporting kidney care, and the rising incidence of diabetes, a significant contributing factor to CKD.

The nephrology drugs market is expected to see strong growth in the next few years. It will grow to $21.53 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. Anticipated growth in the upcoming period is linked to emerging therapies and innovative drug developments in nephrology, the adoption of precision medicine and personalized treatment approaches, a steady increase in healthcare expenditure, the rise of telehealth and remote patient monitoring, and global health initiatives focused on kidney care.

The expanding prevalence of chronic kidney disease is anticipated to drive growth in the nephrology drugs market. Chronic kidney disease results from gradual kidney damage, leading to reduced blood filtration and potential waste buildup in the body. Nephrology drugs play a vital role in managing this condition, aiming to improve kidney function and slow disease progression. Notably, reports from the Centers for Disease Control and Prevention in July 2022 estimated over 37 million diagnosed cases of chronic kidney disease in the US, primarily affecting individuals aged 65 or older. Similarly, the Kidney Foundation of Canada reported 4 million Canadians grappling with kidney diseases, with diabetes being a prominent contributor to kidney failure, a trend expected to rise further.

The rising incidence of diabetes and hypertension is set to propel the nephrology drug market forward. Diabetes, characterized by high blood glucose levels due to insulin-related issues, and hypertension, denoting consistently high blood pressure, are increasingly prevalent conditions. Both ailments often lead to renal complications, creating a heightened demand for nephrology medications. Notably, the World Health Organization's June 2022 data registered over 2.5 million hypertension patients across 15,000 health institutions, while the Centers for Disease Control's 2022 report identified an estimated 37.3 million global cases of diabetes. Consequently, the prevalence of diabetes and hypertension drives the demand for nephrology drugs due to their association with kidney issues.

Product innovation stands as a prominent trend shaping the nephrology drug market. Key industry players are actively introducing novel drugs and solutions to maintain market relevance. For instance, in March 2022, Zydus Lifesciences Limited launched Oxemia (desidustat), an oral medication for chronic kidney disease. This innovative small-molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor has shown promise in Phase III trials, exhibiting positive safety profiles and beneficial effects on anemia, iron mobilization, and LDL-C reduction in CKD patients. Additionally, this innovation is positioned to alleviate the disease burden by providing cost-effective treatment and enhancing patients' quality of life.

Major companies in the nephrology drugs market prioritize obtaining approvals for innovative products, such as the US Food and Drug Administration's approval of Jardiance (empagliflozin). This medication, belonging to the SGLT-2 family for type 2 diabetes, enhances glucose excretion via the kidneys. In January 2023, Eli Lilly and Company, in collaboration with Boehringer Ingelheim, announced FDA approval of Jardiance tablets. These tablets are being investigated as a potential treatment to reduce the risk of advancing kidney disease and cardiovascular death in adults with chronic kidney disease, signifying a concerted effort among pharmaceutical giants to address evolving consumer needs through innovation and regulatory milestones.

In December 2021, CSL Behring AG, a pharmaceutical company based in Switzerland, completed the acquisition of Vifor Pharma AG for $11.7 billion. This strategic move significantly broadens CSL Behring AG's product portfolio, bringing in a comprehensive line of nephrology products that effectively tackle various conditions, including iron deficiency. Vifor Pharma AG, renowned for its global presence and focus on developing solutions for dialysis and nephrology, aligns seamlessly with CSL Behring AG's goals for expansion, diversification, and product enrichment.

Major companies operating in the nephrology drugs market report are AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Amicus Therapeutics, Chugai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Endo Pharmaceuticals plc.

North America was the largest region in the nephrology drug market in 2023. Europe will be the second-largest growing region in the nephrology drug market in 2023. The regions covered in the nephrology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nephrology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nephrology drugs market consists of sales of invokana, phoslo, renvela, sensipar, and procrit drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.